IJPPR
INTERNATIONAL JOURNAL OF PHARMACY & PHARMACEUTICAL RESEARCH
An official Publication of Human Journals
ISSN 2349-7203
HUMAN

Human Journals
Review Article
April 2024 Vol.:30, Issue:4

A Review on Adverse Drug Reaction

IJPPR
INTERNATIONAL JOURNAL OF PHARMACY & PHARMACEUTICAL RESEARCH
An official Publication of Human Journals
ISSN 2349-7203
HUMAN

Ameena Ayesha Shaik*[1], Meghana Kasana[1], Kavya Gangireddy[1]

[1]Pharm.D Intern of Chalapathi Institute of Pharmaceutical Sciences (Autonomous) Chalapthi nagar, Lam, Guntur, India.

Submitted: 20 March 2024
Accepted: 27 March 2024
Published: 30 April 2024

ijppr.humanjournals.com

Keywords: Adverse Drug Reaction, Assessment of ADRs, Prevention, Pharmacovigilance

ABSTRACT

This review provides a thorough analysis of adverse drug reactions (ADRs), emphasizing their categorization, and contributing variables to their emergence, diagnosis, mitigation, and evaluation. Along with more recent categories, it covers the commonly used classification system that includes type A (augmented) and type B (bizarre) reactions. The impact of several factors on the occurrence of adverse drug reactions (ADRs) is thoroughly investigated. These factors include age, gender, maternity status, fetal development, creatinine clearance, allergies, drinking and smoking habits, drug dose, frequency, polypharmacy, and disease-related factors. The identification of patient subgroups and modifications to treatment are two key strategies for reducing adverse drug reactions (ADRs). Furthermore, different ADR evaluation scales for assessing the probability of drug-related adverse events are discussed, including the WHO-UMC criteria and the Naranjo algorithm. The goal of this thorough analysis is to improve clinical ADR understanding and management. Pharmacovigilance, which is the methodical observation and assessment of adverse drug reactions (ADRs), is essential to guaranteeing the efficacy and safety of medications. It entails gathering, evaluating, and reacting to reports of possible adverse drug reactions (ADRs), helping to uncover new safety issues and improve patient care.

INTRODUCTION:-

A reaction to a medicine that is "noxious, unintended, and occurs at doses normally used in human beings" is the most widely accepted definition of an Adverse Drug Reaction (ADR). This classification, which is still in use today, came from a 1972 World Health Organization (WHO) report on international drug monitoring[1]. On the other hand, there have been significant changes to the nomenclature and classification systems for allergies and anaphylaxis[2].

Currently, there are two widely accepted classification schemes for adverse medication reactions. The most accurate categories are type A, or augmented (dose-dependent and predictable), and type B, or bizarre (dose-independent and unpredictable) recognized and frequently used in critical care reactions. Since then, Types C–F have been included.

TABLE 1 Types of ADRs with examples

TYPE OF ADR	DEFINITION	EXAMPLE
A. Augmented (Pharmacologic) Reactions	Exaggeration of the drug's known pharmacologic effects	Excessive bleeding due to anticoagulants
B. Bizarre Reactions	Unexpected, unrelated to the drug's known actions	An allergic reaction to a non-allergenic drug
C. Chronic Effects	Long-term consequences of drug use	Liver damage from prolonged acetaminophen use
D. Delayed Reactions	Manifests after the discontinuation of drug therapy	Stevens-Johnson Syndrome (Antiepileptic drugs), Drug-induced liver injury (Isoniazid)
E. End-of-Use Reactions	Occur when the drug is abruptly stopped or tapered off	Rebound hypertension after stopping beta-blockers
F. Failure of Therapy	Drugs do not produce the expected therapeutic effect	Antibiotic-resistant infection persists despite treatment

Aronson and Ferner (2003) noted that certain adverse medication reactions did not always fall neatly into a single class and suggested a system based on the patient's susceptibility, time-relatedness, and dose-relatedness. Nonetheless, a large number of medication responses observed in critical care still fall neatly into the original type A and type B categories, which is still simple to use and well-known to medical professionals. Because of this, the Medicines and Healthcare Products Regulatory Agency (MHRA) continues to use it in the process of gathering ADRs[3].Important studies conducted in the United States and the United Kingdom

in the late 20th and early 21st centuries revealed that adverse drug reactions (ADRs) are a frequent occurrence in clinical practice. These include arising at hospital admission, occurring throughout that stay, and presenting after discharge. Research indicates that between 5% and 10% of patients may experience an ADR at admission, during hospitalization, or after discharge, despite numerous prevention measures[4]. The frequency of ADRs has remained largely stable throughout time. Most ADRs do not result in significant systemic symptoms, and it is certain that the approach employed to identify such occurrences will have an impact on the frequency of such events. However, given the linked morbidity and mortality, potential financial consequences, and associated frequency of potential injury, this frequency needs to be carefully considered.

The European Academy of Allergy and Immunology (EAACI) updated its allergy nomenclature, which now includes anaphylaxis, in 2001. "Severe, life-threatening generalized or systemic hypersensitivity reaction" is how they described anaphylaxis. Anaphylaxis can be classified as either allergic or non-allergic, and allergic anaphylaxis can be further separated into IgE-mediated and non-IgE-mediated forms. All non-immune-mediated reactions should be referred to as non-allergic anaphylaxis, and the term "anaphylactoid" is no longer in use[5]. With skin prick testing only able to detect IgE-mediated reactions, this new nomenclature emphasizes the challenges in determining potential anaphylaxis triggers. Establishing causality may necessitate further research, such as intradermal testing, which carries the risk of causing more anaphylaxis. Medications that produce adverse drug reactions through IgE-mediated or non-IgE-mediated pathways are not the only ones that exist. Non-steroidal anti-inflammatory medications (NSAIDs) and Neuromuscular blocking drugs can elicit a response through both routes, hence exacerbating the medical issue.

Factors affecting the development of adverse drug reactions:-

1. AGE

ADRs can be produced by any medication, although not every patient experiences the same quantity and kind of ADRs. One significant factor that influences the probability of ADRs is age. ADRs are more likely to occur in elderly individuals with numerous medical conditions who are taking multiple medications, those with a history of ADRs, and those with a decreased ability to stop taking medications. ADRs are frequent and frequently preventable among older people in the ambulatory healthcare setting, according to a 2003 study by

Debellis et al. about their occurrence and preventability[6]. ADRs with greater severity are probably avoidable. The stages of pharmacological care that involve prescribing and monitoring should be the focus of prevention measures. interventions aimed at enhancing patient compliance with recommended schedules and medication supervision. Because medications are less likely to have been well investigated in these age groups, as well as because drug absorption and metabolism are more unpredictable and variable in the elderly and pediatric population, these patients are especially susceptible to adverse drug reactions (ADRs). ADRs in children must be anticipated and prevented, according to Bates et al. (2001)[7]. ADRs are highly likely to occur in infants and early children since their ability to metabolize drugs has not yet been thoroughly assessed. list the following as potential variables that may influence the development of ADRs in neonates: Digoxin, aminoglycosides, ACE inhibitors, and NSAIDs should be avoided by newborns due to their underdeveloped renal tubular function, which occurs before the age of eight weeks (De-gregori et al., 2009)[8].Neonates physiological hypoalbuminemia influences medication dosage. When handling medications that have a high protein binding capacity, like NSAIDs, caution is advised (Anderson and Lynn, 2009)[9].Because newborns have low body fat, medications that dissolve fat may have an impact on them . For a number of reasons, older individuals have a higher chance of getting an ADR. They probably take a number of prescription and over-the-counter medications due to their numerous health issues. The liver's capacity to digest medicines declines with age (Budnitz et al., 2007)[10]. Furthermore, compared to younger persons, older people are more than twice as sensitive to ADRs (Hajar, 2003)[11]. The body's water content falls and its proportion of fat tissue to water content rises with age. Because there is less water in older people's bodies to dilute medications that dissolve in fat, they accumulate more in older people's bodies because there is comparatively more fat tissue available for storage. Additionally, the liver's capacity to metabolize a variety of medicines declines with age, and the kidneys' ability to eliminate drugs into the urine also decreases. According to Jimmy and Padma's (2006) research[12], older persons and the elderly had a much greater frequency of ADRs than did people in other age groups. They went on to explain that different age groups experience different types of ADRs; for example, older adults were more likely to experience type A reactions (85.9%) and adults were more likely to experience type B reactions (35%), relative to other age groups. Many medications tend to stay in an older person's body for far longer than they would in a younger person's due to all the changes that come with aging, which lengthens the drug's action and raises the possibility of side effects.

2. GENDER

Numerous medications have different effects on males and females due to biological variances. Body weight, body composition, gastrointestinal tract variables, liver metabolism, and renal function are the anatomical and physiological differences. Women are heavier than men, their organs are smaller, they have more body fat, their stomach motility is different, and their glomerular filtration rate is lower. These variations can impact the pharmacokinetics and pharmacodynamics of the medications, affecting drug absorption, distribution, metabolism, and excretion, as well as how the body responds to them. The impact on ADRs varies depending on gender. There may be sex differences in the frequency and severity of adverse drug reactions (ADRs) to antiretroviral medications, according to a study on these disparities (Ofotokun and Pomeroy, 2003)[13]. Females have a higher active hepatic enzyme CYP3A4, which has distinct effects on drug metabolism than males (El-Eraky and Thomas, 2003)[14]. They further proposed that when medications that prolong cardiac repolarization are administered, women are more likely than males to experience torsade de pointes ventricular tachycardia. Approximately 25% more days per year than men, women limit their activities due to acute and chronic health issues, and they spend 40% more days in bed annually than males (Legato, 1998)[15]. Compared to men, women between the ages of 17 and 44 see doctors and stay in hospitals twice as often. Excluding reproductive and other sex-specific illnesses almost completely eliminates the gap in hospital stay; nevertheless, the difference in ambulatory care remains about 30%. When all sex-specific diseases are taken out, women continue to see doctors 10–20% more frequently than men after the age of 45, although males are more likely to be hospitalized (Ensom, 2000)[16]. One of the most consistent observations in health research is that women report symptoms of physical illness at higher rates than men. Still unresolved is whether this is due to clinical differences in morbidity or disease severity, or to differences in the following: illness behavior women are more likely than men to interpret discomfort as symptoms; symptom perception – women's attentiveness to body discomfort increases their perception of symptoms and evaluation of those symptoms as illness; or symptom reporting – women may be more likely to recall and report symptoms (Verbrugge, 1985; Ahmed et al., 2009)[17].

3. MATERNITY STATUS

Treatment for drugs is impacted by pregnancy. The medicine has an impact on women, but it also exposes the fetus to adverse drug reactions. Pregnancy causes a number of physiological

changes that may impact the pharmacokinetics and pharmacodynamics of drugs. These changes include an increase in total blood volume of 30–40% (1500–1800 ml), an increase in extravascular volume during the second and third trimesters that results in a decrease in the plasma concentration of iron and some drugs, an improvement in renal function with a 30% increase in renal plasma flow and a 50% increase in GFR, a decrease in serum protein of 1–1.5 lower, which means that drugs excreted by the kidneys would have a higher rate of excretion. Cardiovascular changes are indicated by an increase in cardiac output of approximately 32% as a result of an elevated heart rate (10–15 bpm). Pregnancy causes a decrease in the GIT's motility, acidity, and tone, which may interfere with the absorption or excretion of drugs and, ultimately, impact drug metabolism at specific phases of the pregnancy (Duncombe et al., 2008)[18]. During pregnancy, drugs may have an impact on the mother, the embryo, or both. Because medications have the potential to produce dysmorphogenesis and teratogenicity, their effects on fetal organogenesis are extremely important (Pack et al., 2009)[19]. Numerous medications, such as hypertension medications like ACE inhibitors and angiotensin II receptor blockers, can harm a fetus's health and ability to develop normally (Alomar and Strauch, 2010)[20].

4. FETAL DEVELOPMENT

Since it is small, has few plasma proteins that can bind to drug molecules, and has a poor ability to metabolize and excrete drugs, the fetus, which is exposed to any medications circulating in maternal blood, is extremely vulnerable to the effects of pharmaceuticals. As soon as drug molecules enter the fetus, they may result in further ADRs or teratogenicity, or morphological abnormalities (Brundage, 2002)[26]. The first, second, and third trimesters are used to categorize gestational age. Depending on the stage of fetal development, medications have varying effects on the fetus in each trimester. while medications are used during the first trimester of pregnancy, while embryonic organs are forming, drug teratogenicity is most likely to occur (Holmes et al., 2001)[27]. When medications are taken throughout the second and third trimesters, adverse drug reactions (ADRs) typically show up as growth retardation, respiratory issues, infection, or bleeding in the neonate (birth to one month) or infant (one month to one year). Overall, the kind and dosage of the medications, the length of the exposure, and the stage of fetal growth and development at the time of exposure all influence the effects. The fetus may be impacted by medications, both medicinal and nontherapeutic (Meloni et al., 2009)[28].

5. CREATININE CLEARANCE CATEGORY

Creatinine clearance, a measure of kidney health, reflects the crucial role renal function plays in medication clearance. A divergence from normal renal profiles has the potential to increase the risk of adverse drug reactions (ADRs) by increasing the toxicity of the drug or decreasing the effectiveness of treatment. Research by Venitz (2000)[21] shows how changes brought on by uremia affect the way the liver metabolizes medications as well as how the kidneys remove them. Sun et al. (2006)[22] clarify further that medication clearance can be decreased by changes in metabolic enzymes and drug transporters brought on by renal failure. As a result, decreased activity of metabolic enzymes can hinder the clearance of drugs, as noted by Naud and colleagues (2008)[23]. Remarkably, renal disorders can affect the excretion of non-renal drugs, making any ailment associated with renal insufficiency susceptible.

6. ALLERGY

Cross-reactive antigens that are not affected by drugs can cause sensitizations, which can lead to medication allergies. Medical literature attests to the presence of this kind of cross-reactivity (Chung et al., 2008)[24]. A second exposure to the causative medication leads to impacted T cells and antibodies entering the elicitation phase, which corresponds to type I to IV immunological reactions (Gell and Coombs Classification), following primary sensitization to the drug. Type I or IV medication allergies account for the majority of reported drug allergies; type II and III reactions are rare (Harboe et al., 2007)[25].

7. ALCOHOL

Alcohol influences how many medications are metabolized and promotes the emergence of adverse drug reactions. The term "alcohol drug interaction" describes the potential for alcohol to alter the rate at which ADRs develop, increasing their toxicity or harming the patient in a pharmacokinetic or pharmacodynamic way (Bruce et al., 2008)[29]. When alcohol is used with some medications, adverse drug reactions (ADRs) can include headaches, nausea, vomiting, sleepiness, fainting, lack of coordination, hypotension, and many other symptoms (Krupski et al., 2009)[30]. If a patient with peptic ulcer, ex-peptic ulcer, or gastritis takes alcohol along with NSAIDs, severe ulceration may result in internal bleeding (Kim et al., 2009)[31]. Drinking alcohol continuously triggers enzymes that convert some medications into harmful compounds that can harm the liver. Additionally, alcohol can amplify the sedative and narcotics' inhibitory effects at the brain's site of action. Alcohol may impair liver function, leading to liver cirrhosis and hepatitis, which in turn impair the liver's capacity to

metabolize medicines, particularly those that are processed by the liver and those that have first-pass metabolism. For instance, liver issues make beta blockers more hazardous (Reuben, 2006)[32]. Drug interactions will result from this, so doctors and pharmacists need to alert patients to the potential health risks associated with alcohol-drug interactions (Brown et al., 2007)[33]. Given that age and alcohol use are linked to numerous health issues, older individuals may be more vulnerable to the negative effects of alcohol-drug interactions (Pringle et al., 2005)[34].

8. SMOKING

According to Woo et al. (2009)[35], smoking is a risk factor for several illnesses, including cancer, cardiovascular disease, and peptic ulcers. By acting as a strong inducer of the hepatic cytochrome P-450 (CYP) isoenzymes 1A1, 1A2, and potentially 2E1, it also influences liver enzymes, which in turn impacts the metabolic process (Tomlinson et al., 2005)[36]. Numerous medications are hepatic CYP1A2 substrates, and smoking can increase the metabolism of these pharmaceuticals, which can lead to a clinically meaningful reduction in pharmacologic effects (Faber and Fuhr, 2005)[37]. Tobacco usage is the root cause of these medication interactions rather than nicotine. Nicotine can interfere with the pharmacologic effects of several medications because it activates the sympathetic nervous system (Hukkanen et al., 2005)[38]. Theophylline, flecainide, insulin, oral contraceptives, beta-blockers, thiothixene, and H2 blockers are among the medications whose therapeutic responses can be impacted by smoking, according to additional research findings from throughout the world (Himmelmann et al., 2003)[39].

9. DRUG DOSE AND FREQUENCY

Many factors, such as whether a medication should be taken in the morning, in the evening, or right before bed, might influence drug dosing and the emergence of ADRs. Aspirin has a stronger antiplatelet impact in the evening than it does in the morning, and taking bisphosphonates right before bed may cause esophagitis (Hermida et al., 2005)[40]. Dosing must be taken into account as a factor that could influence the emergence of ADRs.

10. POLYPHARMACY

The concurrent use of many drugs, known as polypharmacy, dramatically increases the risk of adverse drug reactions (ADRs). The risk increases with the quantity of pharmaceuticals consumed, which frequently leads to an unequal rise in the frequency and seriousness of

adverse drug reactions. Although there are several definitions for polypharmacy, the basic idea is that patients are prescribed more prescriptions than are clinically necessary, which increases the possibility of adverse drug reactions (ADRs). Polypharmacy can be caused by a number of things, such as having several medical illnesses, seeing multiple prescribers at once, and patient actions including not taking medications as prescribed or cutting corners. Drug interactions, duplications, additive effects, or prescription cascades where medications are given to manage the bad effects of others may all result in polypharmacy-induced adverse drug reactions (ADRs), which can set off a cycle of increasing pharmaceutical use. Polypharmacy symptoms, which are frequently misinterpreted as signs of aging or illness, might lead to more prescriptions for medications, worsening the situation. Research indicates a disconcerting frequency of inappropriate medicine usage in the elderly population, which is associated with heightened chances of unfavorable consequences like acute kidney failure and dementia[41]. ADR risk is further increased by non-prescription pharmaceutical additions and complicated treatment regimens, which may have synergistic toxicities. Delays in communication between patients and healthcare professionals can worsen polypharmacy, increasing the risk of adverse drug reactions and unnecessary prescriptions. Furthermore, polypharmacy may hurt a patient's nutritional health, especially in the case of elderly patients, and may even result in malnutrition. In light of these hazards, managing polypharmacy is essential to reducing the harm caused by ADRs, boosting patient adherence, and improving therapeutic results.

11.DISEASE-RELATED FACTORS

Having coexisting conditions increases the risk of adverse drug reactions (ADRs). Drug-disease interactions increase the likelihood of adverse drug reactions (ADRs) when co-occurring conditions are present. The body's reaction to pharmaceuticals can be changed by diseases like diabetes, peptic ulcer disease, hypertension, and renal failure. This could result in higher dosages and associated adverse drug reactions. Certain medications used to treat one illness can make another worse. For example, beta-blockers can make asthma worse or make it more difficult to control diabetes. Certain drugs might make acute or chronic conditions worse[42]. For example, congestive heart failure can get worse when taking calcium channel blockers. ADRs can also be more common among people with diseases like AIDS, who are more likely to have symptoms like Stevens-Johnson syndrome and toxic epidermal necrolysis. ADR risks are also increased by infections and immune system dysfunction.

DIAGNOSING ADVERSE DRUG REACTION:-

One of the worst imitators in medicine is ADRs; they frequently imitate "traditional diseases" and show up in every bodily system. Drug-related issues in patients .A hospital admission can manifest in a variety of ways, such as weakness or sleepiness, hemorrhagic or biochemical disturbances (such as acute kidney injury, electrolyte imbalance, or anemia), bleeding, gastrointestinal problems, hypoglycemia, or infections linked to medical care, like Clostridium difficile. But less common signs, including drug-induced lupus, fixed drug eruptions, drug-induced eosinophilia, or drug-induced angioedema, call for a higher degree of caution and skepticism from the doctor, who has to work really hard to find the cause. In order to prevent future adverse drug reactions (ADRs) and determine whether there may be a link between a presenting complaint or subsequent finding and an ADR, a thorough medication history is essential. A drug's causal relationship can be established using a variety of criteria[44]. Certain investigations can sometimes help identify an ADR by supplying objective proof of the reaction and verifying a medication-induced illness. For instance, organ-specific harm combined with drug or metabolite accumulation inside cells (such as indinavir crystalluria and nephropathy)[45].

PREVENTING ADVERSE DRUG REACTION:-

While certain adverse drug reactions (ADRs) are unpredictably occurring, like anaphylaxis in a patient following a single, unremarkable exposure to an antibiotic containing penicillin, many can be avoided with sufficient planning and observation. Avoidability or Preventability generally refers to situations in which the drug treatment plan is not feasible when taking into account known conditions or is not in line with current evidence-based practice[43]. 10 According to epidemiological research, between one-third and one-half of ADRs are (at least possibly) preventable; yet, it is far simpler to identify preventability in retrospect. Reducing the likelihood of an adverse drug reaction (ADR) can, however, be a significant strategy for lowering the risk of patient injury. Two fundamental actions can be taken to stop an ADR from happening:

1. Determine which patient subgroup is most likely to be sensitive to the negative outcome and adjust the treatment option appropriately.

2. Make sure the treatment strategy minimizes any potential side effects.

Identifying susceptibility:

Understanding the susceptibilities of your patients can help you prescribe less and lower the chance of an adverse drug reaction. These prior ADRs will be identified by the patient's medication history, preventing re-exposure to the drug. In other situations, risk factors such include ethnicity, age, gender, and pregnancy status can be used to estimate the likelihood of an adverse drug reaction (ADR). For instance, due to the possibility of ACE inhibitor-induced angioedema, guidelines from the National Institute for Health and Care Excellence recommend that patients of African or Caribbean heritage be prescribed an angiotensin-II receptor blocker rather than an ACE inhibitor for hypertension. Pharmacogenetics, which predicts who is more likely to experience a certain adverse drug reaction, is beginning to provide more individualized medication alternatives.

TREATMENT:

Prescribe carefully and sensibly to minimize errors that can lead to adverse drug reactions. Treatment plans should take into account and minimize any potential negative effects. For instance, co-prescription of folic acid in conjunction with methotrexate can lessen the likelihood of folate deficiency-related side effects. Similarly, electrolyte and renal function monitoring is important while using diuretics or really active medications. All of these instances can stop treatment-emergent side effects, albeit their applicability may be restricted because monitoring guidelines are frequently insufficient or unclear. It's crucial to keep in mind that cautious prescribing may help prevent medication usage entirely, and conservative or nonpharmacological approaches should always be taken into account in treatment plans[46]. All things considered, to lower the likelihood of an ADR and stop such "avoidable" reactions from happening in practice, a systems approach including several techniques, the patient, and all healthcare personnel is needed[47].

ADVERSE DRUG REACTION ASSESSMENT SCALE:

Adverse drug reaction (ADR) probability scales are used in India, to determine the possibility that an adverse event is connected to a particular prescription[48]. ADR probability scales that are frequently used include:

1. Algorithm Naranjo: One of the most popular methods for determining the likelihood that a side effect is drug-related is the Naranjo algorithm. It provides points based on factors like the time interval between the drug's administration and the reaction's commencement, the

existence of competing theories, the patient's prior drug experience, and the patient's reaction to the medication's withdrawal or reintroduction.

2. Uppsala Monitoring Center, World Health Organization (WHO-UMC) Standards: According to the WHO-UMC criteria, ADRs are categorized as certain, probable, plausible, unlikely, or unclassified depending on variables like the temporal link, information about challenges and retests, and the existence of confounding variables.

3. Liverpool Causality Assessment Tool (LCAT): The Liverpool Adverse Drug Reaction (ADR) Causality Assessment Group created this more recent tool. It offers a methodical way to evaluate the clinical plausibility, chronological link, and available data for determining the cause of suspected ADRs**.**

4. Rousseau-Uclaf Causality Assessment Method (RUCAM): RUCAM is an additional algorithmic method for determining whether a medication and an adverse event are causally related. It takes into account variables including the time link, information about challenges and answers, risk considerations, and the existence of competing theories.

5. Schumock and Thornton Scale: This scale considers the temporal association, the response to a retest, and the exclusion of other factors to assess the likelihood of an adverse drug reaction.

PHARMACOVIGILANCE:

"The science and activities related to the detection, assessment, understanding, and prevention of adverse events or any other drug-related problem" is the definition of pharmacovigilance.

To guarantee pharmaceutical businesses and medical regulators adhere to excellent vigilance practices, new laws were implemented in the European Union in 2012. The duties and responsibilities of pertinent stakeholders in relation to drug safety are clearly defined in this new guidance. The guidelines have implemented a more rigorous surveillance program for biological agents with black triangle status and novel pharmaceutical compounds, meaning they need extra monitoring. This is a noteworthy change[48].

For the past 50 years, mechanisms for voluntary reporting, including the UK's Yellow Card Scheme run by the Medicines and Healthcare Products Regulatory Agency (MHRA) and the Commission on Human Medicines (CHM), have been the cornerstone for identifying

possible adverse drug reactions. In the wake of the thalidomide debacle in the late 1950s, the scheme was established in 1964. The program gathers information on suspected adverse drug reactions (ADRs) associated with all licensed and unlicensed medications and vaccines, including those that are prescribed or bought over-the-counter, by self-reporting. Only four pieces of information are needed for a report to be considered valid: an identifying reporter, a response, a suspected medical substance, and an identifiable patient. Nonetheless, reporters are urged to offer as many details as they can, i.e. to give assessors more information and a clinical context. Around 25,000 reports are still received by the UK program annually, giving drug regulators insight into the prevalence of ADRs. Sadly, underreporting is still a major problem; it is believed that less than 5% of all ADRs are actually recorded. This restricts the systems' capacity to provide precise incidence data. The MHRA and NHS England jointly released a warning in 2014 titled "Improving Medication Error Incident Reporting and Learning." This includes the automatic reporting of adverse drug reactions (ADRs) to the Yellow Card Scheme of pharmaceutical errors reported to the National Reporting and Learning System (NRLS).

Patients are taking an increasingly active role in their own treatment management. All patients are now actively encouraged to report adverse drug reactions (ADRs) after an early evaluation of patient Yellow Card reporting demonstrated the effectiveness of this strategy.

Online reporting tools and the Yellow Card app have mainly replaced paper reports (on the original yellow cards). Integrated reporting, which delivers ADR data directly to central agencies for processing prior to input into national and international databases, is another feature of electronic health records utilized in general practice and in certain hospitals. Although frequently used for pharmacovigilance, spontaneous reporting systems work best when adverse events are uncommon and unusual (less than 1% of treated patients) and when the occurrence is indicative of a drug-induced.

There are many other methods and data streams used in pharmacovigilance, including formal drug safety studies, published data, pharmaceutical company data from periodic safety update reports (PSURs) and shared international data. However, regulators and scientists are also looking at the ability of other ‘big data’ sources, such as social media, to detect early signals; this remains an exciting and largely unexplored area of research.

PHARMACOVIGILANCE IN INDIA

Under the supervision of the Central Drugs Standard Control Organization (CDSCO), Ministry of Health and Family Welfare, the Pharmacovigilance Program of India (PvPI) facilitates the reporting of adverse drug reactions (ADRs) in India. An outline of India's ADR reporting procedure is provided below:

1. Healthcare Professional Reporting: The PvPI encourages healthcare professionals, such as doctors, pharmacists, nurses, and other allied health workers, to report suspected adverse drug reactions. There are several avenues via which reporting can be done, including:

- PvPI online reporting portal: By using the online reporting portal on the PvPI website, medical practitioners can electronically submit ADR reports.
- ADR reporting forms: PvPI offers standardized forms for ADR reporting, which can be completed and sent to designated reporting centers via email, fax, or regular mail.
- Mobile applications: PvPI has created applications for cell phones and tablets that make it easy for medical practitioners to report adverse drug reactions.

2. Consumer Reporting: Customers may also contact the PvPI directly to report suspected ADRs. This can be accomplished through the following:

- PvPI online reporting portal: To submit ADR reports, consumers can visit the PvPI website's online reporting portal.
- Toll-free helpline: PvPI provides consumers with a toll-free helpline to report ADRs or to get support with reporting.

3. Adverse Drug Reaction Monitoring Centers (AMCs): Throughout India's medical colleges and institutions, the PvPI has set up AMCs. A vital role in gathering, compiling, and transmitting ADR reports to the National Coordination Centre (NCC) for pharmacovigilance is played by these AMCs, which also function as focal points for ADR reporting.

4. National Coordination Center (NCC): The NCC for pharmacovigilance is in charge of managing the PvPI's general operations. It gets ADR reports from AMCs, analyzes data, looks for signals, and tells pertinent parties about safety-related matters.

5. Collaboration with WHO-UMC: For global pharmacovigilance initiatives, the PvPI works with the WHO-UMC, the Uppsala Monitoring Centre of the World Health Organization.

Through this partnership, access to global databases, pharmacovigilance training, and expertise are made easier.

6. Confidentiality and Security: Reporters and patients participating in ADR reporting are guaranteed confidentiality and anonymity thanks to the PvPI. Reporters' and patients' private information is kept private, and only aggregate data is utilized for reporting and analysis needs.

7. Feedback and Communication: Through newsletters, bulletins, and safety warnings, PvPI informs the public, regulatory bodies, and healthcare professionals about safety-related information. It also gives reporters feedback on the status of their ADR reports.

To improve patient safety and the standard of healthcare, the overall goal of the ADR reporting system in India is to encourage the prompt discovery, assessment, and management of ADRs. The effectiveness of pharmacovigilance activities in the nation depends on sustained efforts to increase awareness, improve stakeholder participation, and expedite reporting procedures[48].

CONCLUSION:

In conclusion, adverse drug reactions (ADRs) affect patients of all ages and genders and pose a serious threat to healthcare. ADR incidence and severity can be influenced by several variables, including age, gender, pregnancy status, renal function, allergy, lifestyle decisions like alcohol and tobacco use, drug dosage, polypharmacy, and disease-related factors. A multidisciplinary strategy including patients, pharmacovigilance programs, regulatory agencies, and healthcare professionals is needed to identify and prevent ADRs. Even though certain ADRs are unpredictably occurring, many can be prevented with cautious prescription, close observation, and patient education. To increase patient safety, pharmacovigilance initiatives like the Pharmacovigilance Program of India (PvPI) are essential for collecting and evaluating ADR reports. In general, continual initiatives to raise awareness, improve reporting procedures, and put preventive measures in place are crucial to minimizing the cost of ADRs and enhancing worldwide healthcare results.

REFERENCES:

1. International drug monitoring: the role of national centres. Report of a WHO meeting. World Health Organ Tech Rep Ser. 1972;498:1-25. PMID: 4625548.
2. Aronson JK, Ferner RE. Joining the DoTS: a new approach to classifying adverse drug reactions. BMJ. 2003 Nov 22;327(7425):1222-5. doi: 10.1136/bmj.327.7425.1222. PMID: 14630763; PMCID: PMC274067.

3. Malinovsky JM, Decagny S, Wessel F, Guilloux L, Mertes PM. Systematic follow-up increases incidence of anaphylaxis during adverse reactions in anesthetized patients. Acta Anaesthesiol Scand. 2008 Feb;52(2):175-81. doi: 10.1111/j.1399-6576.2007.01489.x. Epub 2007 Nov 13. PMID: 18005384.
4. Cook T. NAP6 Anaphylaxis; what and why? Royal College of Anaesthetists Bulletin 2013; 82: 42–3.
5. Pandit JJ, Andrade J, Bogod DG, Hitchman JM, Jonker WR, Lucas N, Mackay JH, Nimmo AF, O'Connor K, O'Sullivan EP, Paul RG, Palmer JH, Plaat F, Radcliffe JJ, Sury MR, Torevell HE, Wang M, Hainsworth J, Cook TM; Royal College of Anaesthetists and the Association of Anaesthetists of Great Britain and Ireland. The 5th National Audit Project (NAP5) on accidental awareness during general anaesthesia: summary of main findings and risk factors. Anesthesia. 2014 Oct;69(10):1089-101. doi: 10.1111/anae.12826. PMID: 25204236.
6. Debellis K., Field T.S., Gurwitz J.H., Harrold L.R., Rothschild J., Seger A.C. Incidence and preventability of adverse drug events among older persons in the ambulatory setting. *JAMA.* 2003;289(9):1107–1116.
7. Bates D.W., Clapp M.D., Federico F., Goldmann D.A., Kaushal R., Landrigan C. Medication errors and adverse drug events in pediatric inpatients. *JAMA.* 2001;285(16):1107–1116.
8. De-gregori S., Ranzani G.N., Borghesi A., Regazzi M., Stronati M. Drug transporters and renal drug disposition in the newborn. *J. Matern. Fetal Neonatal Med.* 2009;22:31–37.
9. Anderson G.D., Lynn A.M. Optimizing pediatric dosing: a developmental pharmacologic approach. *Pharmacotherapy.* 2009;29(6):680–690.
10. Budnitz D.S., Shehab N., Kegler S.R., Richards C.L. Medication use leading to emergency department visits for adverse drug events in older adults. *Ann. Intern. Med.* 2007;147:755–765.
11. Hajar E.R. Adverse drug reaction risk factors in older outpatients. *Am. J. Geriatr. Pharmacother.* 2003;1:82–89.
12. Jimmy J., Padma G.M.R. Pattern of adverse drug reactions notified by spontaneous reporting in an Indian tertiary care teaching hospital. *Pharmacol. Res.* 2006;54:226–233.
13. Ofotokun I., Pomeroy C. Sex differences in adverse reactions to antiretroviral drugs. *Top. HIV Med.* 2003;11(2):55–59.
14. El-Eraky H., Thomas S.H.L. Effects of sex on the pharmacokinetic and pharmacodynamic properties of quinidine. *Br. J. Clin. Pharmacol.* 2003;56:198–204.
15. Legato M.J. Women's health: not for women only. *Int. J. Fertil.* 1998;43:65–72.
16. Ensom M.H. Gender-based differences and menstrual cycle-related changes in specific diseases: implications for pharmacotherapy. *Pharmacotherapy.* 2000;20(5):523–539.
17. Verbrugge L.M. Gender and health: an update on hypotheses and evidence. *J. Health Soc. Behav.* 1985;26:156–182.
18. Duncombe D., Wertheim E.H., Skouteris H., Paxton S.J., Kelly L. How well do women adapt to changes in their body size and shape across the course of pregnancy? *J. Health Psychol.* 2008;13(4):503–515.
19. Pack A.M., Davis A.R., Kritzer J., Yoon A., Camus A. Antiepileptic drugs: are women aware of interactions with oral contraceptives and potential teratogenicity. *Epilepsy Behav.* 2009;14(4):640–644.
20. Alomar M.J., Strauch C.C. A prospective evaluation of antihypertensive medications safety and efficacy in United Arab Emirates private hospitals. *Am. J. Pharmacol. Toxicol.* 2010;5(2):89–94.
21. Venitz R. Effect of chronic renal failure on the disposition of highly hepatically metabolized drugs. *Int. J. Clin. Pharmacol. Ther.* 2000;38(5):245–253.
22. Sun H., Frassetto L., Benet L.Z. Effects of renal failure on drug transport and metabolism. *Pharmacol. Ther.* 2006;109(1–2):1–11.
23. Naud J., Michaud J., Leblond F.A., Lefrancois S., Bonnardeaux A., Pichette V. Effects of chronic renal failure on liver drug transporters. *DMD.* 2008;36(1):124–128.
24. Chung C.H., Mirakhur B., Chan E. Cetuximab-induced anaphylaxis and IgE specific for galactose-α-1,3-galactose. *N. Engl. J. Med.* 2008;358(11):1109–1117.
25. Harboe T., Johansson S.G., Florvaag E., Oman H. Pholcodine exposure raises serum IgE in patients with previous anaphylaxis to neuromuscular blocking agents. *Allergy.* 2007;62(12):1445–1450.
26. Brundage S.C. Preconception health care. *Am. Fam. Physician.* 2002;65:2507–2514.
27. Holmes L.B., Harvey E.A., Coull B.A., Huntington K.B., Khoshbin S., Hayes A.M. The teratogenicity of anticonvulsant drugs. *N. Engl. J. Med.* 2001;344:1132–1138.

28. Meloni P., D'Angeli I., Piazze J., Cerekya A., Simari T., Pala A. First trimester PAPP-A levels associated with early prediction of pregnancy induced hypertension. *Hypertens. Pregnancy.* 2009;28(4):361–368.
29. Bruce R.D., Altice F.L., Fried G.H. Pharmacokinetic drug interactions between drugs of abuse and antiretroviral medications: implications and management for clinical practice. *Exp. Rev. Clin. Pharmacol.* 2008;1(1):115–127.
30. Krupski A., Campbell K., Joesch J., Lucenko B., Roy-Byrne P. Impact of access to recovery services on alcohol/drug treatment outcomes. *J. Subst. Abuse Treat.* 2009;37(4):435–442.
31. Kim B.H., Yi S., Kim J.W., Lim K.S., Kim K., Lee B.W. Influence of alcohol on the hemodynamic effects and pharmacokinetic properties of mirodenafil: a single-dose, randomized-sequence, open-label, crossover study in healthy male volunteers in Korea. *Clin. Ther.* 2009;31(6):1234–1243.
32. Reuben A. Alcohol and the liver. *Curr. Opin. Gastroenterol.* 2006;22(3):263–271.
33. Brown R.L., Dimond A.R., Hulisz D., Saunders L.A., Bobula J.A. Pharmacoepidemiology of potential alcohol–prescription drug interactions among primary care patients with alcohol-use disorders. *J. Am. Pharm. Assoc.* 2007;47(2):135–139.
34. Pringle K.E., Ahern F.M., Heller D.A., Gold C.H., Brown T.V. Potential for alcohol and prescription drug interactions in older people. *J. Am. Geriatr. Soc.* 2005;53(11):1930–1936.
35. Woo D., Khoury J., Haverbusch M.M., Sekar P., Flaherty M.L., Kleindorfer D.O. Smoking and family history and risk of aneurysmal subarachnoid hemorrhage. *Neurology.* 2009;72:69–72.
36. Tomlinson J.E., McMahon A.D., Chaudhuri R. Efficacy of low and high dose inhaled corticosteroid in smokers versus non-smokers with mild asthma. *Thorax.* 2005;60:282–287.
37. Faber M.S., Fuhr U. Time response of cytochrome P450 1A2 activity on cessation of heavy smoking. *Clin. Pharmacol. Ther.* 2005;76:178–184.
38. Hukkanen J., Jacob P., Benowitz N.L. Metabolism and disposition kinetics of nicotine. *Pharmacol. Rev.* 2005;57:79–115.
39. Himmelmann A., Jendle J., Mellen A. The impact of smoking on inhaled insulin. *Diabetes Care.* 2003;26:677–682.
40. Hermida R.C., Ayala D.E., Calvo C., López J.E. Aspirin administered at bedtime, but not on awakening affects ambulatory blood pressure in hypertensive patients. *J. Am. Coll. Cardiol.* 2005;46(6):975–983.
41. Bushardt R.L., Massey E.B., Simpson T.W., Ariail J.C., Simpson K.N. Polypharmacy: misleading, but manageable. *Clin. Interv. Aging.* 2008;3(2):383–389.
42. Hanses F., Zierhut S., Schölmerich J., Salzberger B., Wrede C. Severe and long lasting cholestasis after high-dose co-trimoxazole treatment for pneumocystis pneumonia in HIV-infected patients a report of two cases. *Int. J. Infect. Dis.* 2009;13(6):467–469.
43. Ferner RE , Aronson JK . Preventability of drug-related harms - part I: a systematic review. Drug Saf 2010 ; 33 : 985 – 94 .
44. Naranjo CA , Busto U , Sellers EM et al . A method for estimating the probability of adverse drug reactions . Clin Pharmacol Ther 1981 ; 30 : 239 – 45 .
45. Hauben M , Aronson JK . Gold standards in pharmacovigilance: the use of definitive anecdotal reports of adverse drug reactions as pure gold and high-grade ore . Drug Saf 2007 ; 30 : 645 – 55 .
46. Coleman JJ , Ferner RE , Evans SJ . Monitoring for adverse drug reactions . Br J Clin Pharmacol 2006 ; 61 : 371 – 8 .
47. Rommers MK , Teepe-Twiss IM , Guchelaar HJ . Preventing adverse drug events in hospital practice: an overview . Pharmacoepidemiol Drug Saf 2007 ; 16 : 1129 – 35 .
48. World Health Organization . The importance of pharmacovigilance . Geneva : World Health Organization , 2002.